|
1) Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer. 2009; 8: 109-17
|
|
|
|
2) Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004; 64: 2634-38
|
|
|
|
|
|
3) Shirts BH, Burt RW, Mulvihill SJ, et al. A Population-based description of familial clustering of pancreatic cancer. Clin Gastroenterol Hepatorol. 2010; 8: 812-16
|
|
|
|
|
|
4) Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324: 217
|
|
|
|
|
|
5) Tischkowitz MD, Sabbaghian N, Hamel N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009; 137: 1183-6
|
|
|
|
|
|
6) Shi C, Hruban HR, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009; 133: 365-74
|
|
|
|
|
|
7) Kim DH, Crawford B, Ziegler J, et al. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer. 2009; 8: 153-8
|
|
|
|
|
|
8) Whitcomb D, Greer J. Germ-line mutations, pancreatic inflammation, and pancreatic cancer. Clin Gastroenterol Hepatorol. 2009; 7: S29-S34
|
|
|
|
|
|
9) Huxley R, Ansary-Moghaddam A, Berrington de González A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92: 2076-83
|
|
|
|
|
|
10) Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008; 134: 981-7
|
|
|
|
|
|
11) Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008; 134: 95-101
|
|
|
|
|
|
12) Li D, Yeun SCJ, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroentetrology. 2009; 137: 482-8
|
|
|
|
|
|
13) Butler AE, Galasso R, Matveyenko A, et al. Pancreatic duct replication is increased with obesityand type 2 diabetes in humans. Diabetologia. 2010; 53: 21-6
|
|
|
|
|
|
14) Kisfalvi K, Eibl G, Sinnett-Smith J, et al. Metformin disrupts crosstalk between G protein-doupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009; 69: 6539-45
|
|
|
|
|
|
15) Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1receptors and G protein-coupled receptor signaling systems: a novel target for the tntidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010; 6: 2505-11
|
|
|
|
|
|
16) Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009; 10: 88-95
|
|
|
|
|
|
17) Raimondi S, Lowenfels AB, Morselli-Labate AM, et al. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010; 24: 349-58
|
|
|
|
|
|
18) Rebours V, Boutron-Ruault MC, Schnee M, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol. 2008; 103: 111-9
|
|
|
|
|
|
19) Rebours V, Boutron-Ruault MC, Jooste V, et al. Mortality rate and risk factors in patients with hereditary pancreatitis: uni- and multidimensional analyses. Am J Gastroenterol. 2009; 104: 2312-7
|
|
|
|
|
|
20) Grocock CJ, Rebours V, Delhaye MN, et al. The variable phenotype of the p. A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut. 2010; 59: 357-63
|
|
|
|
|
|
21) Shimosegawa T, Kume K, Satoh K. Chronic pancreatitis and pancreatic cancer: prediction and mechanism. Clin Gastroenterol Hepatol. 2009; 7 (Suppl): S23-8
|
|
|
|
|
|
22) Johansen D, Manjer J, Regner S, et al. Pre-diagnostic levels of anionic trypsinogen, cationic trypsinogen, and pancreatic secretory trypsin inhibitor in relation to pancreatic cancer risk. Pancreatology. 2010; 10: 229-37
|
|
|
|
|
|
23) Uehara H, Nakaizumi A, Ishikawa O, et al. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut. 2008; 57: 1561-5
|
|
|
|
|
|
24) Tanno S, Nakano Y, Koizumi K, et al. Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas. 2010; 39: 36-40
|
|
|
|
|
|
25) Ingkakul T, Sadakari Y, Ienaga J. Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg. 2010; 251: 70-5
|
|
|
|
|
|
26) Kanno A, Satoh K, Hirota M. Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol. 2010 Apr 10[Epub ahead of print]
|
|
|
|
|
|
27) Iodice S, Gandini S, Maisonneuve P, et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008; 393: 535-45
|
|
|
|
|
|
28) Lin Y, Kikuchi S, Tamakoshi A, et al. Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. Int J Cancer. 2007; 120: 2665-71
|
|
|
|
|
|
29) Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010; 170: 791-802
|
|
|
|
|
|
30) Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight. A systematic review and meta-analysis. BMC Public Health. 2009; 9: 88, doi: 10. 1186/1471-2458-9-88
|
|
|
|
|
|
31) Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009; 301: 2553-62
|
|
|
|
|
|
32) Tramacere I, Scotti L, Jenab M, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010; 126: 1474-86
|
|
|
|
|
|
33) Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol. 2007; 102: 2696-707
|
|
|
|
|
|
34) Jacobs EJ, Rodriguez C, Newton CC, et al. Family history of various cancers and pancreatic cancer mortalityin a large cohort. Cancer Causes Control. 2009; 20: 1261-9
|
|
|
|
|
|
35) Bao Y, Spiegelman D, Li R, et al. History of peptic ulcer disease and pancreatic cancer risk in men. Gastroenterology. 2010; 138: 541-9
|
|
|
|
|
|
36) Laiyemo AO, Kamangar F, Marcus PM, et al. Serum pepsinogen level, atrophic gastritis and the risk of incident pancreatic cancer-A prospective cohort study. Cancer Epidemiology. 2009; 33: 368-73
|
|
|
|
|
|
37) Lindkvist B, Johansen D, Borgström A, et al. A prospective study of Helicobacter pylori in relation to the risk for pancreatic cancer. BMC Cancer. 2008; 8: 321 doi: 10. 1186/1471-2407-8-321
|
|
|
|
|
|
38) Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res. 2010; 70; 1015-23
|
|
|
|
|
|
39) Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009; 41: 986-90
|
|
|
|
|
|
40) Hassan MM, Li D, El-Deeb AS, et al. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol. 2008; 26: 4557-62
|
|
|
|
|
|
41) Zhang Y, Coogan PF, Palmer JR, et al. A case-control study of reproductive factors, female hormone use, and risk of pancreatic cancer. Cancer Causes Control. 2010; 21: 473-8
|
|
|
|
|